A Phase 2 interventional study of TCD601 in Kidney Transplantation, sponsored by ITB-Med LLC. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by ITB-Med LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation
ITB-Med LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
Biological: TCD601
TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
Biological: TCD601
Investigational Product
The Proportion of Patients Off Immunosuppression With Good Safety and Tolerability
The proportion of patients off immunosuppression with good safety and tolerability at 24 months assessed by immunosuppression dosing; Serum creatinine (estimated glomerular filtration rate \[eGFR\]); Incidents of Chimeric Transition Syndrome (CTS) and biopsy proven acute rejection (BPAR); Renal biopsy
Time frame: 24 months
The Incidence of de Novo Donor-specific Antibody
Time frame: 24 months
The Incidence of Biopsy Proven Acute Rejection, Death and Graft Loss
Time frame: 24 months
Study was early terminated and participants were not fully enrolled into Arm 1. No participants were enrolled in Arm 2.
| Milestone | Arm 1 |
|---|---|
| Started | 4 |
| Completed | 0 |
| Not completed | 4 |
| Withdrew: Sponsor decision; early termination | 4 |
The proportion of patients off immunosuppression with good safety and tolerability at 24 months assessed by immunosuppression dosing; Serum creatinine (estimated glomerular filtration rate \[eGFR\]); Incidents of Chimeric Transition Syndrome (CTS) and biopsy proven acute rejection (BPAR); Renal biopsy
| Participants | Arm 1 |
|---|---|
| The Proportion of Patients Off Immunosuppression With Good Safety and Tolerability | 1 |
| Participants | Arm 1 |
|---|---|
| The Incidence of de Novo Donor-specific Antibody | 3 |
| Participants | Arm 1 |
|---|---|
| The Incidence of Biopsy Proven Acute Rejection, Death and Graft Loss | 2 |
Collected over From enrollment to end of follow up, up to 24 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Event | Arm 1 |
|---|---|
| Engraftment syndromeImmune system disorders | 2/4 |
| InfluenzaInfections and infestations | 1/4 |
| PyelonephritisInfections and infestations | 1/4 |
| Small intestinal obstructionGastrointestinal disorders | 1/4 |
| Post procedural urine leakInjury, poisoning and procedural complications | 1/4 |
| Event | Arm 1 |
|---|---|
| LeukopeniaBlood and lymphatic system disorders | 4/4 |
| LymphopeniaBlood and lymphatic system disorders | 4/4 |
| NeutropeniaBlood and lymphatic system disorders | 3/4 |
| thrombocytopeniaBlood and lymphatic system disorders | 3/4 |
| Donor specific antibody presentInvestigations | 3/4 |
Study was early terminated and participants were only assigned to Arm 1 (4 doses). No participants were enrolled into Arm 2 (5 doses). No donors were enrolled into the study.
| Age, Continuous(years) | Arm 1 |
|---|---|
| Mean | 40.0 ± 18.57 |
| Sex: Female, Male(Participants) | Arm 1 |
|---|---|
| Female | 0 |
| Male | 4 |
| Race (NIH/OMB)(Participants) | Arm 1 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 1 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1 |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 2 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Arm 1 |
|---|---|
| United States | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2023 to primary completion in Oct 2025, 33 months.
Results were first posted in Nov 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Siplizumab
ITB-Med LLC